Skye Bioscience, Inc.SKYENASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +223.66% | +41.61% | +2.56% | +2.18% | -0.77% |
| Weighted Average Shares Diluted Growth | +223.66% | +41.61% | +2.56% | +2.18% | -0.77% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -96.80% | -95.72% | +67310.00% | -100.00% | +106.79% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +509.39% | -31.68% | -40.22% | -49.32% | -61.09% |
| Book Value per Share Growth | +0.00% | -46.96% | -41.51% | -57.61% | -70.39% |
| Debt Growth | -90.13% | -91.48% | -92.75% | +68.51% | -39.94% |
| R&D Expense Growth | +389.68% | +269.76% | +251.52% | +91.62% | +47.17% |
| SG&A Expenses Growth | +82.55% | +8.48% | -9.72% | -15.78% | -24.77% |